PropertyValue
?:abstract
  • [ ]pegfilgrastim accounts for more than 5% of the total cost of cancer care in the OCM - a remarkable figure for a supportive drug The authors estimated that this resulted in a potential cost savings of between $500,000 and $1 7 million per 100 patients treated, with reductions in out-of-pocket costs for women, especially for those without commercial insurance, compared with the previously accepted standard of care Since biosimilar introduction, the reimbursement rate has fallen by $93 per year
is ?:annotates of
?:creator
?:journal
  • HEM/ONC_Today
?:license
  • unk
?:publication_isRelatedTo_Disease
?:source
  • WHO
?:title
  • Bringing drug costs down a \'peg\' or two
?:type
?:who_covidence_id
  • #928129
?:year
  • 2020

Metadata

Anon_0  
<http://www.w3.org/1999/02/22-rdf-syntax-ns#type> <http://purl.org/net/provenance/ns#DataItem>
<http://www.w3.org/1999/02/22-rdf-syntax-ns#type> <http://www.w3.org/2004/03/trix/rdfg-1/Graph>
<http://xmlns.com/foaf/0.1/primaryTopic> <https://research.tib.eu/covid-19/entity/thnuxzms>
<http://xmlns.com/foaf/0.1/topic> Anon_0
<http://www.ontologydesignpatterns.org/cp/owl/informationrealization.owl#realizes> <https://research.tib.eu/covid-19/data/entity/thnuxzms>
<http://purl.org/net/provenance/ns#createdBy>
Anon_1   (more)
expand all